Technology
MacuCLEAR’s lead proprietary compound, MC1101, is being developed to treat the dry form of AMD. Challenging conventional wisdom, this novel compound is delivered in eye drop form.
While novel in this ophthalmic application, the active ingredient of MC1101 has been approved for systemic use by the FDA as an oral antihypertensive drug. Its safety and toxicity profile is well characterized. MC1101 has been granted 505 (b) 2 status and Fast Track eligibility by the FDA.